UCB SA (UCBJF)
284.50
-0.66
(-0.23%)
USD |
OTCM |
Dec 10, 15:37
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 54.05B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 65.60% |
| Valuation | |
| PE Ratio | 38.23 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 7.425 |
| Price to Book Value | 9.537 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 1.578 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 46.44% |
Profile
| UCB SA engages in the research and development of biopharmaceuticals products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium. |
| URL | http://www.ucb.com |
| Investor Relations URL | https://www.ucb.com/investors/ |
| HQ State/Province | Brussels Region |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Feb. 25, 2026 (est.) |
| Last Earnings Release | Jul. 31, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Apr. 28, 2025 |
Ratings
Profile
| UCB SA engages in the research and development of biopharmaceuticals products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium. |
| URL | http://www.ucb.com |
| Investor Relations URL | https://www.ucb.com/investors/ |
| HQ State/Province | Brussels Region |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Feb. 25, 2026 (est.) |
| Last Earnings Release | Jul. 31, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Apr. 28, 2025 |